Aposense

About:

Aposense is a molecular imaging and drug development company, with a pipeline of products, based on its apoptosis-based technology.

Website: http://www.aposense.com

Top Investors: Pontifax, Docor International Management, Clal Biotechnology Industries, Ziegler Meditech Equity Partners, Phoenix Insurance

Description:

Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple disease categories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy. Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core. Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel.